Cypress Bioscience - Best Pharma Stocks of 2007

Company: Cypress Bioscience
Starting stock price: $7.64
Ending stock price: $11.03
Percent Change: 44.37%

Details: Last year Cypress Bioscience marked several big milestones. On May 22, the company wrapped up a second Phase III trial of its drug candidate milnacipran, a dual-reuptake inhibitor that acts on norepinephrine and serotonin. The company is trying to commercialize it for use against fibromyalgia. Then, May 31, Cypress launched a public offering of 4.7 million shares.

Cypress then presented the results to the American College of Rheumatology in November: Milnacipran delivered “statistically significant and clinically meaningful improvements in both pain and other core symptoms associated with fibromyalgia,” the company announced. By year’s end, the company and its development partner Forrest Laboratories submitted a new drug application with the FDA. The compound already is approved for use in more than 50 countries.